Ozanimod for the treatment of relapsing remitting multiple sclerosis
@article{Rasche2018OzanimodFT, title={Ozanimod for the treatment of relapsing remitting multiple sclerosis}, author={L. Rasche and F. Paul}, journal={Expert Opinion on Pharmacotherapy}, year={2018}, volume={19}, pages={2073 - 2086} }
ABSTRACT Introduction: Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. Extensive clinical experience has become available for the related compound fingolimod, favoring the sphingosine 1-phosphate therapeutic concept. Off-target effects have been attributed to its low receptor specificity and have prompted the development of next generation sphingosine 1-phosphate receptor… CONTINUE READING
Topics from this paper
9 Citations
Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
- Medicine
- Neurology international
- 2020
- PDF
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
- Medicine
- Journal of comparative effectiveness research
- 2020
- 4
Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
- Medicine
- Revue neurologique
- 2019
- 3
Therapeutic Approaches toward Multiple Sclerosis: Where Do We Stand and Where Are We Headed?
- Medicine
- 2019
- 1
Effects of Massage Therapy on Multiple Sclerosis: a Case Report
- Medicine
- International journal of therapeutic massage & bodywork
- 2020
- PDF
References
SHOWING 1-10 OF 207 REFERENCES
Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
- Medicine
- Expert review of neurotherapeutics
- 2016
- 17
An update on cladribine for relapsing-remitting multiple sclerosis
- Medicine
- Expert opinion on pharmacotherapy
- 2017
- 11
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- Medicine
- The Lancet Neurology
- 2016
- 90
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
- Medicine
- The New England journal of medicine
- 2010
- 1,792
- PDF
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- Medicine
- The Lancet Neurology
- 2013
- 145
- Highly Influential
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
- Medicine
- The New England journal of medicine
- 2010
- 2,061
- PDF
Both cladribine and alemtuzumab may effect MS via B-cell depletion
- Medicine
- Neurology: Neuroimmunology & Neuroinflammation
- 2017
- 49
- PDF
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
- Medicine
- Annals of neurology
- 2011
- 317
- PDF
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
- Medicine
- Multiple sclerosis and related disorders
- 2018
- 12
Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
- Medicine
- Expert opinion on pharmacotherapy
- 2015
- 15